Earticle

현재 위치 Home

Original Article

국내 가와사키병 환아의 약물사용
Drug Utilization in Korean Children with Kawasaki Disease

첫 페이지 보기
  • 발행기관
    한국임상약학회 바로가기
  • 간행물
    한국임상약학회지 KCI 등재 바로가기
  • 통권
    제27권 제3호 (2017.09)바로가기
  • 페이지
    pp.127-135
  • 저자
    차승희, 제남경
  • 언어
    한국어(KOR)
  • URL
    https://www.earticle.net/Article/A310747

※ 기관로그인 시 무료 이용이 가능합니다.

4,000원

원문정보

초록

영어
Background: Kawasaki disease (KD) is an acute febrile, systemic vasculitis as a leading cause of acquired heart disease in children. Intravenous immunoglobulin G (IVIG) and aspirin are the standard initial therapy in the treatment of acute KD. The purpose of this study was to investigate drug utilization in children with KD, and to compare “IVIG + high-dose aspirin” and “IVIG + moderate-dose aspirin” in preventing cardiac complications. Methods: We analyzed pediatric patient sample data compiled by the Health Insurance Review & Assessment Service from 2010 to 2015. We identified patients with KD using the KCD-6 code of M30.3. We excluded patients in chronic phase or ≥10 years. We also excluded patients who were diagnosed KD in November or December. Drug utilization pattern were assessed in acute KD patients and 30-day and 60-day cardiac complications were investigated between “IVIG + high-dose aspirin” group and “IVIG + moderate-dose aspirin” group. Results: In acute phase, IVIG was administered to 95.8% patients, and 57.1% patients were prescribed moderate-dose aspirin and 25% patients were with highdose aspirin. Steroid use was rapidly increased from 4.0% in 2010 to 11.3% in 2015. Both 30-day and 60-day cardiac complications occurred less in “IVIG + high-dose aspirin” group compared to “IVIG + moderate-dose aspirin” group, but not statistically significant (0.9% vs 1.8%, p=0.252 for 30-day complication rate; 1.5% vs 2.7%. p=0.073 for 60-day complication rate). Conclusion: We were not able to demonstrate which aspirin therapy is superior for preventing cardiac complications in acute KD patients and further research is warranted.

목차

ABSTRACT
 연구 방법
  연구자료 및 연구대상
  KD 급성기 약물치료
  KD 합병증 발생률
  Aspirin 용량별 합병증 예방효과
  생명윤리위원회 심의
  통계분석
 연구 결과
  연구대상자 특징
  KD 급성기 약물치료
  KD 합병증 발생률
  Aspirin 용량별 합병증 예방효과
 고찰 및 결론
 감사의 말씀
 참고문헌

저자

  • 차승희 [ SungHee Cha | 부산대학교 약학대학, 부산보훈병원 약제실 ]
  • 제남경 [ Nam Kyung Je | 부산대학교 약학대학 ] Corresponding author

참고문헌

자료제공 : 네이버학술정보

간행물 정보

발행기관

  • 발행기관명
    한국임상약학회 [Korean College of Clinical Pharmacy]
  • 설립연도
    1
  • 분야
    의약학>약학
  • 소개
    합리적 약물치료(rational pharmacotherapy)의 보장 및 증진을 궁극목적으로 하며 이를 달성하기 위해 임상약학의 발전과 회원 상호간의 친목을 도모한다.

간행물

  • 간행물명
    한국임상약학회지 [Korean Journal of Clinical Pharmacy]
  • 간기
    계간
  • pISSN
    1226-6051
  • 수록기간
    1991~2026
  • 등재여부
    KCI 등재
  • 십진분류
    KDC 518 DDC 615

이 권호 내 다른 논문 / 한국임상약학회지 제27권 제3호

    피인용수 : 0(자료제공 : 네이버학술정보)

    함께 이용한 논문 이 논문을 다운로드한 분들이 이용한 다른 논문입니다.

      페이지 저장